miRNAs expression signature potentially associated with lymphatic dissemination in locally advanced prostate cancer

Abstract

Background Prostate cancer is one of the most common and socially significant cancers among men. The aim of our study was to reveal changes in miRNA expression profiles associated with lymphatic dissemination in prostate cancer and to identify the most prominent miRNAs as potential prognostic markers for future studies. Methods High-throughput miRNA sequencing was performed for 44 prostate cancer specimens taken from Russian patients, with and without lymphatic dissemination (N1 – 20 samples; N0 – 24 samples). Results We found at least 18 microRNAs with differential expression between N0 and N1 sample groups: miR-182-5p, miR-183-5p, miR-96-5p, miR-25-3p, miR-93-5p, miR-7-5p, miR-615-3p, miR-10b, miR-1248 (N1-miRs; elevated expression in N1 cohort; p < 0.05); miR-1271-5p, miR-184, miR-222-3p, miR-221-5p, miR-221-3p, miR-455-3p, miR-143-5p, miR-181c-3p and miR-455-5p (N0-miRs; elevated expression in N0; p < 0.05). The expression levels of N1-miRs were highly correlated between each other (the same is applied for N0-miRs) and the expression levels of N0-miRs and N1-miRs were anti-correlated. The tumor samples can be divided into two groups depending on the expression ratio between N0-miRs and N1-miRs. Conclusions We found the miRNA expression signature associated with lymphatic dissemination, in particular on the Russian patient cohort. Many of these miRNAs are well-known players in either oncogenic transformation or tumor suppression. Further experimental studies with extended sampling are required to validate these results.

Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review)

“…A number of studies have recently manifested the association of miR-222-3p dysregulation with cancer initiation and progression (29)(30)(31). Despite recent developments in cancer diagnosis and treatment, there are still numerous problems associated with the pathogenesis of cancer progression, disease recurrence and drug resistance.…”

“…As well as having a strong potential in the diagnosis of cancer, miR-222-3p also serves an important role in predicting the prognosis of patients with cancer. An increasing number of studies has demonstrated that dysregulated miR-222-3p expression can predict the progression and poor prognosis of patients with cancer, including prostate cancer and papillary thyroid carcinoma ( 30 , 31 ).…”

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

“…When comparing the remaining potential miRNAs, according to the present bioinformatics analysis (miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, and miR-592), all were suggested with important roles in PC screening [61], aggressiveness [8,62,63], and recurrence [7,18,64], or even new etiological values [65] were suggested. These miRNAs have also been highlighted with carcinogenic effects in other tumors, such as endometrial [66,67], osteosarcoma [68], hepatocellular [69], renal [17,70], or colorectal [71], among others [72][73][74].…”

Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs

“…• 12 of 42 with an  in malignancy [233]   in PCa vs BPH [263]   in PCa [264] [265]   in PCa and metastases [266]   viability, migration, invasion [264]  overrides radiation-induced cell cycle arrest [267]  associated with disease recurrence [266] --  in PCa [199]   in patients with LN metastases [269]  promotes PCa progression [270,271]   expression predicts poor survival [272]  blood: BPH vs PCa [208]  seminal plasma: disease aggressiveness [   favors progression and self-renewal [129]   correlates with early clinical failure [286]  urine: cancer cell -macrophage signalling [287]  urine: PCa vs healthy [288]  negative regulation by lncRNA TTTY15 [289]  suppresses AR via Myc [290] in NEPC tissues [194] • 12 of 42 with an  in malignancy [233]   in PCa vs BPH [263]   in PCa [264] [265]   in PCa and metastases [266]   viability, migration, invasion [264]  overrides radiation-induced cell cycle arrest [267]  associated with disease recurrence [266] --  in PCa [199]   in patients with LN metastases [269]  promotes PCa progression [270,271]   expression predicts poor survival [272]  blood: BPH vs PCa [208]  seminal plasma: disease aggressiveness [273]  plasma: disease prediction [274]  serum: PCa diagnosis [275] -  in PCa [199]   in advanced PCa [260]   in patients with LN metastases …”